Comparing Cognition Therapeutics (NASDAQ:CGTX) & VectivBio (NASDAQ:VECT)

VectivBio (NASDAQ:VECT) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Volatility and Risk

VectivBio has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500. Comparatively, Cognition Therapeutics has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.

Institutional & Insider Ownership

43.3% of Cognition Therapeutics shares are held by institutional investors. 9.7% of VectivBio shares are held by company insiders. Comparatively, 20.8% of Cognition Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares VectivBio and Cognition Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VectivBio	$27.34 million	20.97	-$93.74 million	N/A	N/A
Cognition Therapeutics	N/A	N/A	-$25.79 million	($0.92)	-0.46

Cognition Therapeutics has lower revenue, but higher earnings than VectivBio.

Analyst Ratings

This is a summary of recent recommendations and price targets for VectivBio and Cognition Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VectivBio	0	0	0	0	N/A
Cognition Therapeutics	0	2	4	0	2.67

Cognition Therapeutics has a consensus price target of $8.00, indicating a potential upside of 1,800.24%. Given Cognition Therapeutics’ higher possible upside, analysts plainly believe Cognition Therapeutics is more favorable than VectivBio.

Profitability

This table compares VectivBio and Cognition Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VectivBio	N/A	N/A	N/A
Cognition Therapeutics	N/A	-118.11%	-84.49%

Summary

Cognition Therapeutics beats VectivBio on 6 of the 9 factors compared between the two stocks.

About VectivBio

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.

About Cognition Therapeutics

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.